Ideaya Biosciences Inc (IDYA)

Currency in USD
23.10
+0.69(+3.08%)
Closed·
After Hours
23.35+0.25(+1.06%)
·
IDYA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IDYA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
22.2223.11
52 wk Range
13.4540.74
Key Statistics
Prev. Close
22.41
Open
22.52
Day's Range
22.22-23.11
52 wk Range
13.45-40.74
Volume
849.96K
Average Volume (3m)
1.15M
1-Year Change
-38.53%
Book Value / Share
10.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IDYA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
47.15
Upside
+104.13%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings downwards for the upcoming period

Ideaya Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Ideaya Biosciences Inc Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Ideaya Biosciences Inc SWOT Analysis


Precision Oncology Pionee
IDEAYA Biosciences leads in targeted cancer therapeutics, with darolutamide for uveal melanoma and IDE397 for MTAP-deficient cancers as key pipeline assets
Financial Fortress
With $1.2 billion in cash reserves and a robust current ratio, IDEAYA is well-positioned to fund its ambitious R&D pipeline and potential commercialization efforts
Catalysts on the Horizon
Anticipate pivotal clinical readouts, including darolutamide's PFS results in late 2025, and strategic R&D updates that could significantly impact IDEAYA's market valuation
Analyst Optimism
RBC Capital Markets sets a $61 price target, reflecting confidence in IDEAYA's potential to revolutionize uveal melanoma treatment and expand its precision oncology portfolio
Read full SWOT analysis

Compare IDYA to Peers and Sector

Metrics to compare
IDYA
Peers
Sector
Relationship
P/E Ratio
−6.1x−1.0x−0.5x
PEG Ratio
0.09−0.050.00
Price/Book
2.1x2.3x2.6x
Price / LTM Sales
289.2x8.9x3.3x
Upside (Analyst Target)
99.1%318.8%43.5%
Fair Value Upside
Unlock7.6%6.8%Unlock

Analyst Ratings

12 Buy
2 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 47.15
(+104.13% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-0.88 / -0.79
Revenue / Forecast
6.00M / 3.81M
EPS Revisions
Last 90 days

IDYA Income Statement

People Also Watch

37.72
EXEL
+0.88%
2.840
ABSI
-2.74%
21.590
AAOI
-3.31%
138.66
KRYS
+1.88%
16.42
ARWR
+2.24%

FAQ

What Stock Exchange Does Ideaya Biosciences Trade On?

Ideaya Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Ideaya Biosciences?

The stock symbol for Ideaya Biosciences is "IDYA."

What Is the Ideaya Biosciences Market Cap?

As of today, Ideaya Biosciences market cap is 2.02B.

What Is Ideaya Biosciences's Earnings Per Share (TTM)?

The Ideaya Biosciences EPS (TTM) is -3.79.

When Is the Next Ideaya Biosciences Earnings Date?

Ideaya Biosciences will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is IDYA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Ideaya Biosciences Stock Split?

Ideaya Biosciences has split 0 times.

How Many Employees Does Ideaya Biosciences Have?

Ideaya Biosciences has 131 employees.

What is the current trading status of Ideaya Biosciences (IDYA)?

As of 09 Aug 2025, Ideaya Biosciences (IDYA) is trading at a price of 23.10, with a previous close of 22.41. The stock has fluctuated within a day range of 22.22 to 23.11, while its 52-week range spans from 13.45 to 40.74.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.